Julie Gerberding, MD, MPH (Video Available)

Speaker: Julie Gerberding, MD, MPH, at CEO at Foundation for the National Institutes of Health, Former Director, CDC


Talk Title: Building Pandemic Resilience through Disruptive Public Health Innovation.

Dr. Julie Louise Gerberding is the Chief Executive Officer of the Foundation for the National Institutes of Health (FNIH).  The FNIH creates and manages research alliances with public and private institutions in support of the mission of the NIH to enhance health, lengthen life, and reduce illness and disability.  The FNIH works with its partners to accelerate biomedical research that addresses some of the most pressing health challenges in the United States and across the globe.

Formerly, Dr. Gerberding was Executive Vice President and Chief Patient Officer at Merck & Co., Inc., where she was responsible for patient engagement, strategic communications, global public policy, population health, and corporate responsibility. She joined Merck in 2010 as President of Merck Vaccines to help increase global access to important vaccines among those who need them most.

Dr. Gerberding was Director of the United States CDC from 2002-2009, where she led the agency through more than 40 emergency responses to public health crises, including SARS in 2003.  She currently co-chairs the CSIS Commission on Strengthening America’s Health Security and is a board trustee at Mayo Clinic and Case Western Reserve University and serves as a board director for HilleVax, Afternext Health Tech, and SummerBio.

Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks.  In 2018, she was selected as the Healthcare Businesswomen Association’s Woman of the Year.

Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University (CWRU).  She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco (UCSF) and is board certified in Internal Medicine and Infectious Diseases. She served as a tenured member of the infectious diseases faculty at UCSF and the hospital epidemiologist at San Francisco General Hospital and is currently an Adjunct Associate Professor of Medicine at UCSF and an Adjunct Professor of Medicine at CWRU.  Dr. Gerberding received a Masters of Public Health at the University of California, Berkeley.  She is a member of the National Academy of Medicine, a member of the Council on Foreign Relations, and a fellow of the Infectious Diseases Society of America and the American College of Physicians. 


Keloth VK, Banda JM, Gurley M, Heider PM, Kennedy G, Liu H, Liu F, Miller T, Natarajan K, V Patterson O, Peng Y, Raja K, Reeves RM, Rouhizadeh M, Shi J, Wang X, Wang Y, Wei WQ, Williams AE, Zhang R, Belenkaya R, Reich C, Blacketer C, Ryan P, Hripcsak G, Elhadad N, Xu H. Representing and Utilizing Clinical Textual Data for Real World Studies: An OHDSI Approach. Journal of biomedical informatics 2023.

Toce MS, Michelson KA, Hudgins JD, Olson KL, Monuteaux MC, Bourgeois FT. Association of prescription drug monitoring programs with benzodiazepine prescription dispensation and overdose in adolescents and young adults. Clinical toxicology (Philadelphia, Pa.) 2023.

Brown T, de Salazar Munoz PM, Bhatia A, Bunda B, Williams EK, Bor D, Miller JS, Mohareb A, Thierauf J, Yang W, Villalba J, Naranbai V, Garcia Beltran W, Miller TE, Kress D, Stelljes K, Johnson K, Larremore D, Lennerz J, Iafrate AJ, Balsari S, Buckee C, Grad Y. Geographically skewed recruitment and COVID-19 seroprevalence estimates: a cross-sectional serosurveillance study and mathematical modelling analysis. BMJ open 2023.

El-Hayek C, Barzegar S, Faux N, Doyle K, Pillai P, Mutch SJ, Vaisey A, Ward R, Sanci L, Dunn AG, Hellard ME, Hocking JS, Verspoor K, Boyle DI. An evaluation of existing text de-identification tools for use with patient progress notes from Australian general practice. International journal of medical informatics 2023.

Patik I, Redhu NS, Eran A, Bao B, Nandy A, Tang Y, El Sayed S, Shen Z, Glickman J, Fox JG, Snapper SB, Horwitz BH. The IL-10 receptor inhibits cell extrinsic signals necessary for STAT1-dependent macrophage accumulation during colitis. Mucosal immunology 2023.